Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis

References

• Michishita R, Matsuda T, Kawakami S, et al. Hypertension and hyperglycemia and the combination thereof enhanced the incidence of chronic kidney disease (CKD) in middle-aged and older males. Clin Exp Hypertens. 2017;39(37):1.
   PubMedGoogle Scholar
• Sharbaf FG, Assadi F. Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease. Pediatr Nephrol. 2018; 33(3):1–5.
   PubMedGoogle Scholar
• Vervloet MG, Ballegooijen AJV. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018;93(5):1060–1072.
   PubMed Web of Science ®Google Scholar
• Haider DG, Lindner G, Wolzt M, et al. Hyperphosphatemia is an independent risk factor for mortality in critically ill patients: results from a cross-sectional study. PLOS One. 2015;10(8):e0133426.
   PubMed Web of Science ®Google Scholar
• Shang D, Xie Q, Ge X, et al. Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients. BMC Nephrol. 2015;16(1):1–9.
   Google Scholar
• Francesco L, Lucia DV, Leano V, et al. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opin Drug Saf. 2014;13(5):551–561.
   PubMed Web of Science ®Google Scholar
• Stevens LA, Ognjenka D, Savannah C, et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15(3):770–779.
   PubMed Web of Science ®Google Scholar
• Hans-Gernot A, Johan B, Rolfdieter K, et al. Two-year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005;20(8):1653–1661.
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009;54(4):619–637.
   PubMed Web of Science ®Google Scholar
• Jamal SA, Ben V, Paolo R, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268–1277.
   PubMed Web of Science ®Google Scholar
• Damment SJ, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokine. 2008;47(9):553–563.
   Google Scholar
• Michael P, Lynne P, Kerry D, et al. Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding. Ren Fail. 2012;34(3):263–270.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang YX, Yu XQ, et al. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: a multicenter, double-blind, randomized, controlled trial in mainland China. BMC Nephrol. 2013;14(1):29.
   PubMedGoogle Scholar
• Green S. Cochrane handbook for systematic reviews of interventions: Cochrane book series. Naunyn-Schmiedebergs Archiv Für Experimentelle Pathologie Und Pharmakologie. 2011;5(2):S38.
   Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Al-Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant. 2005; 20(4):775–782.
   PubMed Web of Science ®Google Scholar
• Chang YM, Tsai SC, Shiao CC, Liou HH, et al. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients. Clin Exp Nephrol. 2017;21(5):908–916.
   PubMed Web of Science ®Google Scholar
• Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (fosrenol) efficacy and tolerability in the treatment of hyperphosphatemia patients with end-stage renal disease. Clin Nephrol. 2005;63(06):461–470.
   PubMedGoogle Scholar
• Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006;65(03):191–202.
   PubMedGoogle Scholar
• Finn WF, Joy MS, Hladik G, et al. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004;62(09):193–201.
   PubMedGoogle Scholar
• Fujii H, Kono K, Nakai K, et al. Effects of lanthanum carbonate on coronary artery calcification and cardiac abnormalities after initiating hemodialysis. Calcif Tissue Int. 2018;102(3):310–320.
   PubMed Web of Science ®Google Scholar
• Gao Y, Wang G, Li Y, et al. Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease. J Nephrol. 2019;32(2):265–272.
   PubMed Web of Science ®Google Scholar
• Hutchison A, Whelton A, Thadhani R, et al. Long-term mortality and bone safety in patients with end-stage renal disease receiving lanthanum carbonate. Nephron. 2018;140(4):265–274.
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Gill M, Copley JB, et al. Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients. BMC Nephrol. 2013;14(1):40.
   PubMedGoogle Scholar
• Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005;100(1):c8–c19.
   PubMedGoogle Scholar
• Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003;42(1):96–107.
   PubMed Web of Science ®Google Scholar
• Kalil RS, Michael F, William S, et al. Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study. Clin Nephrol. 2012;78(1):1–9.
   PubMed Web of Science ®Google Scholar
• Komaba H, Kakuta T, Suzuki H, et al. Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol Dial Transplant. 2015;30(1):107–114.
   PubMed Web of Science ®Google Scholar
• Kyu LY, Young HC, SugKyun S, et al. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study. Clin Nephrol. 2013;79(2):136–142.
   PubMed Web of Science ®Google Scholar
• Prajapati VA, Galani VJ, Shah PR. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis . Saudi J Kidney Dis Transpl. 2014;25(3):530–538.
   PubMedGoogle Scholar
• Scaria PT, Gangadhar R, Pisharody R. Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease. Indian J Pharmacol. 2009;41(4):187–191.
   PubMed Web of Science ®Google Scholar
• Shigematsu T; Lanthanum Carbonate Group. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2008;70(5):404–410.
   PubMed Web of Science ®Google Scholar
• Takashi S. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial. 2010;12(1):55–61.
   Web of Science ®Google Scholar
• Sprague SM, Ross EA, Nath SD, et al. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009;72(4):252–258.
   PubMed Web of Science ®Google Scholar
• Takahara Y, Matsuda Y, Takahashi S, et al; Lanthanum Carbonate Study Group. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. Clin Nephrol. 2014;82(2014)(09):181–190.
   PubMedGoogle Scholar
• Tatsunori T, Keiichi F, Shouichi F, et al. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clin Nephrol. 2012;78(3):216–223.
   PubMed Web of Science ®Google Scholar
• Toussaint ND, Lau KK, Polkinghorne KR, et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrol. 2011;16(3):290–298.
   PubMed Web of Science ®Google Scholar
• Wang X-H, Zhang X, Mu C-J, et al. Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients. J Huazhong Univ Sci Technol. 2015;35(4):508–513.
   PubMedGoogle Scholar
• Wilson R, Zhang P, Smyth M, et al. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Medi Res Opin. 2009;25(12):3021–3028.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang S, Zhao S, et al. Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: a prospective pilot study. Med. 2017;96(45):e8664.
   PubMed Web of Science ®Google Scholar
• Spasovski GB, Aleksandar S, Saso G, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant. 2006;21(8):2217–2224.
   PubMed Web of Science ®Google Scholar
• Sprague SM, Abboud H, Qiu P, et al. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. CJASN. 2009;4(1):178–185.
   PubMed Web of Science ®Google Scholar
• Ogata H, Fukagawa M, Hirakata H, LANDMARK Investigators and Committees, et al. Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the LANDMARK randomized clinical trial. JAMA. 2021;325(19):1946–1954.
   PubMed Web of Science ®Google Scholar
• Mario C, Sandro M, Vincent B. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders? Nephrol Dial Transplant. 2011;26(2):402–407.
   PubMed Web of Science ®Google Scholar
• Sturtevant JM, Hawley CM, Reiger K, et al. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Nephrology. 2004;9(6):406–413.
   PubMed Web of Science ®Google Scholar
• Sekercioglu N, Thabane L, Martínez JP, et al. Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis. PLOS One. 2016; 11(6):e0156891.
   PubMed Web of Science ®Google Scholar
• Mehrotra R, Martin KJ, Fishbane S, et al. Higher-strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. CJASN. 2008; 3(5):1437–1445.
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Barnett ME, Krause R, et al. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis. Clin Nephrol. 2009;71(3):286–295.
   PubMed Web of Science ®Google Scholar
• Bervoets A, Behets G, Roels F, et al. Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure. Kidney Int. 2009;75(4):389–398.
   PubMed Web of Science ®Google Scholar
• Minakuchi H, Yoshida T, Kaburagi N, et al. Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients. Ren Fail. 2020;42(1):799–806.
   PubMed Web of Science ®Google Scholar
• Tatsuzawa M, Ogawa R, Ohkubo A, et al. Influence of proton pump inhibitors and histamine H2 receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing hemodialysis: a retrospective medical chart review. J Pharm Health Care Sci. 2016;2:34.
   PubMed Web of Science ®Google Scholar